Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials
PLOS Medicine · 2025
DOI: 10.1371/journal.pmed.1004616 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PLOS Medicine, 2025. Verfasst von Kirk U Knowlton und 25 weiteren Autor:innen. Beteiligte Einrichtung: Intermountain Heart Institute, Intermountain Medical Center, Salt Lake City, Utah, United States of America. Hauptthemen laut MEDLINE: COVID-19, Immunization, Passive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Anti-SARS-CoV-2 monoclonal antibodies (mAb) reduce the risk of hospitalization in outpatients with mild-to-moderate COVID-19. However, the efficacy of treatment with mAbs and other passive immunotherapies in patients hospitalized with severe COVID-19 is not clear. The objective of this study was to assess the clinical effect of passive immunotherapy and its heterogeneity according to baseline endogenous neutralizing antibody status and SARS-CoV-2 antigen level, in adults hospitalized with SARS-CoV-2 infection and severe COVID-19. Methods and findings We carried out a two-stage individual participant data meta-analysis of six double-blind, randomized, placebo-controlled trials conducted under the Therapeutics for Inpatients with COVID-19 (TICO) and the similarly designed Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) master protocols. Within each trial, three major outcomes (sustained recovery, mortality, and a composite safety outcome) were compared between treatment and placebo using Fine-Gray and Cox proportional hazards models. Trial-specific treatment differences for each of the three outcomes were pooled using a common effect meta-analysis. A total of 3,079 patients hospitalized for COVID-19 were enrolled in the six trials. Only 18% had received at least one dose of an anti-SARS-CoV-2 vaccine. Overall, the median plasma SARS-CoV-2 antigen level was 1,421 (IQR: 231−4,568) pg/mL, and 51% of patients were endogenous neutralizing antibody positive at study entry. The overall summary estimate of sustained recovery rate ratio (RRR) of the treatment versus placebo group was 1.06 (95% CI [0.99,1.14]), but this varied significantly by antibody serostatus. The RRR was 1.16 (95% CI [1.04,1.29]) among seronegative patients and 0.97 (95% CI [0.88,1.07]) in seropositive patients [ p = 0.02 for interaction (the difference in RRR between seropositive and seronegative patients)]. The summary hazard ratio (HR) for mortality comparing treatment to placebo was 0.81 (95% CI [0.64,1.03]) overall, 0.69 (95% CI [0.50,0.95]) in seronegative patients, and 0.96 (95% CI [0.66,1.39]) in seropositive patients (interaction p = 0.18). There was no evidence that the treatment effect on any outcome differed according to antigen level, whether overall or within serostatus subgroups. In regards to the composite safety outcome, the overall summary HR comparing treatment group to placebo was 0.89 (95% CI [0.66,1.21]; Q = 3.47 [ p = 0.63], I 2 = 0.0%), and it was 0.83 (95% CI [0.70,0.99]) and 1.04 (95% CI [0.86,1.26]) in seronegative and seropositive patients, respectively. The main limitation of the methodology is that these results are limited to the analysis of the six trials in ACTIV-3/TICO and ITAC and are not intended to be a complete summary of all trials of passive immunotherapy.
Conclusions
Passive immunotherapy might be a useful treatment option for hospitalized patients with COVID-19 if administered before the appearance of endogenous antibodies. Development of similar passive immunotherapy could also be especially important during the early stages of a viral pandemic, or as novel viral variants emerge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Intermountain Heart Institute, Intermountain Medical Center, Salt Lake City, Utah, United States of America.
- Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States of America.
- Department of Medicine, Division of Pulmonary and Critical Medicine, Duke Medicine, Durham, North Carolina, United States of America.
- Royal Free Hospital and University College, London, United Kingdom.
- Kirby Institute, University of New South Wales Sydney, Sydney, New South Wales, Australia.
- Public Health Institute at Denver Health, Denver Hospital Authority, Denver, Colorado, United States of America.
ORCID-Profile: Kirk U Knowlton, Lianne K Siegel, Nila J Dharan, Robert L Gottlieb, Marie Helleberg, Thomas L Holland, Susana Lazarte, Jeffrey Scott Overcash
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NIAID NIH HHS
- Foundation for the National Institutes of Health
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
Zitieren
APA
Knowlton, K. U., Siegel, L. K., Barkauskas, C. E., Bhagani, S., Dharan, N. J., Gardner, E. M., Gottlieb, R. L., Helleberg, M., Highbarger, H. C., Holland, T. L., Heerfordt, C. K., Lazarte, S., Leither, L. M., Lutaakome, J., Ardelt, M., Mylonakis, E., Ong, S. W. X., Overcash, J. S., Taha, H., …, & STRIVE ACTIV-3/TICO Study Group (2025). Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004616
Vancouver
Knowlton KU, Siegel LK, Barkauskas CE, Bhagani S, Dharan NJ, Gardner EM, et al. Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials. PLOS Medicine. 2025. doi:10.1371/journal.pmed.1004616
BibTeX
@article{Knowlton2025,
author = {Knowlton, Kirk U and Siegel, Lianne K and Barkauskas, Christina E and Bhagani, Sanjay and Dharan, Nila J and Gardner, Edward M and Gottlieb, Robert L and Helleberg, Marie and Highbarger, Helene C and Holland, Thomas L and Heerfordt, Christian Kjer and Lazarte, Susana and Leither, Lindsey M and Lutaakome, Joseph and Ardelt, Magdalena and Mylonakis, Eleftherios and Ong, Sean W X and Overcash, Jeffrey Scott and Taha, Hassan and Tien, Phyllis C and Trautner, Barbara W and Vallee, David and Weintrob, Amy C and Touloumi, Giota and Babiker, Abdel G and STRIVE ACTIV-3/TICO Study Group, STRIVE ACTIV-3/TICO Study Group},
title = {Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials},
journal = {PLOS Medicine},
year = {2025},
doi = {10.1371/journal.pmed.1004616}
}
EUVIMED